Platform Technology Using Ubiquitin to Improve the Delivery and Efficacy of Cytosolic Targeted Toxins


Targeted toxins (TT) are hybrid protein drugs consisting of ligands that bind to the surface of cancer cells and deliver polypeptide toxins that kill malignant cells by inactivating cytosolic protein synthesis and inducing cell death. A major challenge in the construction of targeted toxins is reducing the nonspecific binding of the toxin moiety to normal tissues and increasing the cytotoxicity of the treatment.

To address these issues, the NIH inventors have identified that the protein ubiquitin, a small protein in eukaryotic cells that plays a role in protein recycling, can separate the targeting moiety and the catalytic moiety of a TT in the cytosol of cells. By decoupling the two moieties, the cytotoxicity of the TT treatment can be greatly increased since the catalytic domain remains longer in the cytosol. This technology would be highly useful for all TT and immunotoxins that access the cytosol to either affect cytosolic targets or traffic to further sites of action. To validate this approach, the inventors have tested ubiquitin variants within a TT consisting of anthrax toxin lethal factor N-terminus (LFn) and Pseudomonas exotoxin A catalytic domain (PEIII). Here, they show that the intracellular release of the PEIII (catalytic moiety) is achievable and that ubiquitination of the TT controls the persistence of the TTs in the cytosol and thus controls the observed cytotoxicity.

Potential Commercial Applications: Competitive Advantages:
  • Chimeric or fusion molecules for increasing the efficacy and cytotoxicity of targeted toxins and immunotoxins.
  • Methods for cytosol delivery of targeted toxins to target cells.
 
  • Broadly applicable to all cytotoxic immunoconjugates.
  • Increased stability and cytotoxicity of the TT without affecting the delivery or specificity of the treatment.
  • Therapeutic access to the cytosol and/or trafficking to further sites of action such as the nucleus.
  • Rapid cytosolic release of the catalytic moiety and degradation of the targeting moiety.


Development Stage:
  • Pre-clinical
  • In vitro data available


Related Invention(s):
E-293-1999-0
E-059-2004-0
E-070-2007-2


Inventors:

Stephen Leppla (NIDCR)  ➽ more inventions...

Shihui Liu (NIDCR)  ➽ more inventions...

Christopher Bachran (NIAID)  ➽ more inventions...

Thomas Morley (NIAID)  ➽ more inventions...


Intellectual Property:
US Application No. 61/473,450
PCT Application No. PCT/US2012/032762

Publications:
Tcherniuk S, et al. PMID 15668131
Wang F. PMID 20371697
Heisler I. PMID 12455044

Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:

OTT Reference No: E-150-2011-0
Updated: Sep 29, 2011